Publications by authors named "B Weinbergerova"
Background: Waldenström's macroglobulinemia (WM) is a very rare disease with an incidence 10times lower than that of multiple myeloma. The incidence of WM is also significantly lower than that of the other CD20+ low-grade lymphomas. The rarity of WM is the reason why registration studies of new drugs used for multiple myeloma or the more common CD20+low-grade lymphomas do not cover WM.
View Article and Find Full Text PDFCommunity-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA-EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023-2024 autumn-winter season.
View Article and Find Full Text PDFSingle or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.
J Clin Oncol
January 2025
Purpose: To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60 mg/m with 90 mg/m daunorubicin in the first 7 + 3 induction and one versus two cycles of 7 + 3 induction.
Patients And Methods: Patients age 18-65 years with newly diagnosed AML were randomly assigned to 60 versus 90 mg/m daunorubicin once daily plus cytarabine. Patients with marrow blasts below 5% on day 15 after first induction were randomly assigned to receive a second induction cycle or no second induction cycle.
Article Synopsis
- * Antifungal prophylaxis has reduced IFD occurrences but has also changed the types of fungal pathogens seen, necessitating broader screening methods for early diagnosis and treatment.
- * A study analyzed blood samples from high-risk patients using advanced PCR techniques, revealing that many detectable fungi were typically non-pathogenic, highlighting the need for repeated testing and accurate identification to guide effective treatment.
Article Synopsis
- - Our study looked at fungal infections in patients with acute myeloid leukemia being treated with venetoclax and azacitidine, comparing those who received antifungal prophylaxis (AFP) to those who didn't.
- - Out of 186 patients, only 1 out of 85 (1%) with AFP developed a fungal infection, while 5 out of 101 (5%) without AFP got infected, showing no significant difference between the two groups.
- - Overall, the study found that fungal infections were mostly mild and appeared early in treatment, and they did not significantly impact patient survival or death rates.